Market Price

102.70 

2.22 2.2%

as of May 14 '21

52 Week Range:

67.97 127.68


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Equity (BVPS) 3.77
4.83
5.14
8.01
11.12
13.44
growth rate 28.1% 6.4% 55.8% 38.8% 20.9%
Earnings BIT 263.80
278.00
229.50
252.00
287.80
294.60
409.80
growth rate 5.4% -17.5% 9.8% 14.2% 2.4% 39.1%
Avg.PE 121.07
16.02
15.70
43.93
87.07
70.56
70.56
growth rate -86.8% -2.0% 179.8% 98.2% -19.0% 0.0%
ROA -0.78
-1.51
0.53
6.81
3.58
3.36
2.09
2.46
2.48
growth rate 0.0% 100.0% 1,184.9% -47.4% -6.2% -37.8% 17.7% 0.8%
ROE 161.49
17.56
16.15
9.24
9.54
7.55
growth rate -89.1% -8.0% -42.8% 3.3% -20.9%
ROIC 11.32
7.15
6.67
4.99
5.37
5.30
growth rate -36.8% -6.7% -25.2% 7.6% -1.3%
Cur. Ratio 1.60
1.65
1.52
1.85
2.02
2.26
2.15
2.08
2.57
growth rate 3.1% -7.9% 21.7% 9.2% 11.9% -4.9% -3.3% 23.6%
Quick Ratio 1.09
1.13
1.06
1.31
1.40
1.70
1.70
1.61
2.10
growth rate 3.7% -6.2% 23.6% 6.9% 21.4% 0.0% -5.3% 30.4%
Leverage 4.96
4.86
4.77
4.17
3.68
2.68
growth rate -2.0% -1.9% -12.6% -11.8% -27.2%
Balance Sheet Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Acct.Receivable 338.30
358.00
403.70
372.40
414.80
488.80
555.80
716.40
899.50
growth rate 5.8% 12.8% -7.8% 11.4% 17.8% 13.7% 28.9% 25.6%
Acct.Payable 396.10
375.30
148.10
128.20
143.70
163.20
192.10
255.80
321.00
growth rate -5.3% -60.5% -13.4% 12.1% 13.6% 17.7% 33.2% 25.5%
Cur.Assets 704.70
679.10
687.50
737.50
790.20
1,059.80
1,240.30
1,395.80
2,293.00
growth rate -3.6% 1.2% 7.3% 7.2% 34.1% 17.0% 12.5% 64.3%
Total Assets 3,139.00
2,949.50
3,090.20
3,138.30
3,091.10
3,454.30
4,531.10
6,184.00
7,776.50
growth rate -6.0% 4.8% 1.6% -1.5% 11.8% 31.2% 36.5% 25.8%
Cash 139.00
106.40
74.40
151.30
131.60
288.30
410.20
345.40
953.20
growth rate -23.5% -30.1% 103.4% -13.0% 119.1% 42.3% -15.8% 176.0%
Inventory 118.70
124.90
147.30
144.40
165.60
196.70
220.20
265.30
346.90
growth rate 5.2% 17.9% -2.0% 14.7% 18.8% 12.0% 20.5% 30.8%
Cur.Liabilities 439.30
410.30
453.00
399.00
391.20
469.00
576.90
670.70
893.20
growth rate -6.6% 10.4% -11.9% -2.0% 19.9% 23.0% 16.3% 33.2%
Liabilities 3,489.70
3,360.20
3,457.50
2,498.50
2,455.20
2,730.80
3,444.40
3,895.80
4,271.10
growth rate -3.7% 2.9% -27.7% -1.7% 11.2% 26.1% 13.1% 9.6%
LT Debt 2,640.30
2,656.60
2,685.40
1,857.00
1,832.80
2,055.10
2,649.40
2,715.50
2,820.40
growth rate 0.6% 1.1% -30.9% -1.3% 12.1% 28.9% 2.5% 3.9%
Equity -371.20
634.00
635.90
723.50
1,086.70
1,681.60
2,898.80
growth rate 100.0% 0.3% 13.8% 50.2% 54.7% 72.4%
Common Shares 117.00
117.00
117.00
117.00
121.00
126.00
127.00
133.00
146.00
152.00
growth rate 0.0% 0.0% 0.0% 3.4% 4.1% 0.8% 4.7% 9.8% 4.1%
Cash Flow Statement Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Capital Expenditures 104.20
122.50
122.40
141.00
139.60
139.80
176.50
218.10
465.80
growth rate 17.6% -0.1% 15.2% -1.0% 0.1% 26.3% 23.6% 113.6%
Cash Dividends 36.20
36.20
36.20
36.20
growth rate 0.0% 0.0% 0.0%
Cash From OA 87.90
137.70
178.30
171.80
155.30
299.50
374.50
247.70
440.30
growth rate 56.7% 29.5% -3.7% -9.6% 92.9% 25.0% -33.9% 77.8%
FCF per Share 0.09
0.46
0.90
1.54
0.52
-0.25
growth rate 411.1% 95.7% 71.1% -66.2% -100.0%
Sale Purchase of Stock 1.10
1.20
0.20
948.80
-5.80
growth rate 9.1% -83.3% 474,300.0% -100.0%
FCF 12.00
-16.00
15.00
55.00
31.00
15.00
159.00
198.00
30.00
-26.00
growth rate -100.0% 100.0% 266.7% -43.6% -51.6% 960.0% 24.5% -84.9% -100.0%
Income Statement Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Sales 1,694.80
1,800.30
1,827.70
1,830.80
1,848.10
2,075.40
2,463.40
2,518.00
3,094.30
growth rate 6.2% 1.5% 0.2% 0.9% 12.3% 18.7% 2.2% 22.9%
Op.Income 18.10
-50.90
263.80
278.00
229.50
252.00
287.80
294.60
409.80
growth rate -100.0% 100.0% 5.4% -17.5% 9.8% 14.2% 2.4% 39.1%
IBT 18.60
-23.90
67.40
112.50
144.90
135.60
152.00
160.30
260.40
growth rate -100.0% 100.0% 66.9% 28.8% -6.4% 12.1% 5.5% 62.5%
Net Income 18.10
-50.90
16.20
212.20
111.50
109.80
83.60
137.40
220.70
growth rate -100.0% 100.0% 1,209.9% -47.5% -1.5% -23.9% 64.4% 60.6%
EPS -0.46
-0.21
-0.42
0.14
1.75
0.89
0.87
0.63
0.90
1.14
growth rate 0.0% 0.0% 100.0% 1,150.0% -49.1% -2.3% -27.6% 42.9% 26.7%
Gross Profit 558.60
568.60
598.60
615.30
587.60
654.60
752.60
805.10
983.30
growth rate 1.8% 5.3% 2.8% -4.5% 11.4% 15.0% 7.0% 22.1%
R&D 17.50
12.20
7.60
7.00
6.30
3.30
2.60
growth rate -30.3% -37.7% -7.9% -10.0% -47.6% -21.2%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT 105.00
178.40
84.90
133.30
growth rate 69.9% -52.4% 57.0%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 734.30
899.50
817.10
894.40
growth rate 22.5% -9.2% 9.5%
Acct.Payable 276.20
321.00
329.40
356.90
365.70
growth rate 16.2% 2.6% 8.4% 2.5%
Cur.Assets 1,746.10
2,293.00
2,356.10
2,518.90
2,774.50
growth rate 31.3% 2.8% 6.9% 10.2%
Total Assets 7,079.60
7,776.50
7,984.20
8,198.10
8,769.10
growth rate 9.8% 2.7% 2.7% 7.0%
Cash 608.40
953.20
1,007.00
833.10
988.10
growth rate 56.7% 5.6% -17.3% 18.6%
Inventory 320.30
346.90
406.70
486.20
growth rate 8.3% 17.2% 19.6%
Cur.Liabilities 917.10
893.20
919.70
1,024.00
1,139.20
growth rate -2.6% 3.0% 11.3% 11.3%
Liabilities 4,285.30
4,271.10
4,305.50
4,383.60
4,696.90
growth rate -0.3% 0.8% 1.8% 7.2%
LT Debt 2,802.00
2,820.40
2,839.60
2,840.20
growth rate 0.7% 0.7% 0.0%
Equity 2,187.70
2,898.80
3,072.10
3,455.50
3,713.20
growth rate 32.5% 6.0% 12.5% 7.5%
Common Shares 1.50
1.60
1.60
1.70
1.70
growth rate 6.7% 0.0% 6.3% 0.0%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 151.30
162.30
149.60
189.30
growth rate 7.3% -7.8% 26.5%
Cash Dividends 8.10
8.10
8.10
4.90
growth rate 0.0% 0.0% -39.5%
Cash From OA 121.70
172.70
149.70
74.00
growth rate 41.9% -13.3% -50.6%
Sale Purchase of Stock
growth rate
FCF -29.60
10.40
0.10
-115.30
growth rate 100.0% -99.0% -100.0%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 760.60
947.60
845.70
910.80
1,053.30
growth rate 24.6% -10.8% 7.7% 15.7%
Op.Income 105.00
178.40
84.90
133.30
growth rate 69.9% -52.4% 57.0%
IBT 29.70
179.00
67.40
109.00
317.10
growth rate 502.7% -62.4% 61.7% 190.9%
Net Income 20.90
154.20
82.40
88.40
231.80
growth rate 637.8% -46.6% 7.3% 162.2%
Gross Profit 238.80
334.60
248.90
298.20
365.60
growth rate 40.1% -25.6% 19.8% 22.6%
R&D 0.60
0.80
6.40
5.20
growth rate 33.3% 700.0% -18.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (58.78)

YOY Growth Grade:

D (43.34)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 70.56 34.81 21.07
EPS / Growth 8.2% 2.95 9.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 8.2% 22.4% 26.6%
Future PE 16.36 45.48 48.30
Future EPS 6.48 22.28 31.30
Value Price
MOS %
26.19
-74.5%
250.53
143.9%
373.70
263.9%
MOS Price 13.09 125.26 186.85
IRT 16.40 9.87 8.97

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.